There are no direct pharmacokinetic interactions involving the EPM2A gene, which is crucial in glycogen metabolism and linked to Lafora disease. However, the pharmacodynamic effects of antipsychotic drugs like chlorpromazine, haloperidol, and olanzapine on neurological symptoms possibly influenced by EPM2A dysfunction suggest a need for cautious use in patients with Lafora disease to manage psychiatric symptoms while minimizing potential exacerbation of neurological impairments.